THAR Stock Risk & Deep Value Analysis
THAR
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About THAR Stock
We analyzed THAR using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran THAR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
THAR Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is continued decline in production volumes and grades, coupled with adverse PGM and chrome commodity price movements. Without financial data, the company's ability to absorb these shocks or invest in future growth is unclear, potentially leading to lower revenue and pressure on profitability.
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
High
Competitive
Medium
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Declining Q/Q PGM production, rougher feed grade, and recovery rates.
- ⚠
Complete lack of financial performance metrics (revenue, EPS, margins, cash flow) in the provided research.
- ⚠
No identified strategic vision or competitive advantages to support future growth.
Upcoming Risk Events
- 📅
Further decline in PGM production or grades
- 📅
Continued weakness in PGM/chrome commodity prices
- 📅
Unfavorable regulatory changes in operating jurisdictions
When to Reconsider
- 🚪
Exit if Q3 FY2026 production report shows further significant declines.
- 🚪
Sell if PGM and chrome commodity prices experience a sustained, material downturn.
- 🚪
Exit if the company announces significant equity dilution without a clear growth strategy.
Unlock THAR Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does THAR (THAR) Do?
Market Cap
$187.37M
Sector
Healthcare
Industry
Biotechnology
Employees
2
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic conditions with high unmet need in the United States. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH023 which is phase 1 clinical trial used to treat multiple high value autoimmune indications; and HS1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
Visit THAR WebsiteInvestment Thesis
Investment in Tharisa plc is a speculative bet on a turnaround in production metrics and/or a significant, sustained rally in platinum group metals and chrome prices. The company's current operational data shows headwinds, and there are no clear growth catalysts to justify a 10x potential within 3-5 years without fundamental changes not indicated in the research.
Is THAR Stock Undervalued?
Unlock the full AI analysis for THAR
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
THAR Price Targets & Strategy
12-Month Target
$4.20
Bull Case
$5.50
Bear Case
$3.00
Valuation Basis
Base target reflects current price with slight PGM commodity price recovery and stable operations. Upside assumes mild operational improvement; downside assumes continued production declines and commodity price weakness.
Entry Strategy
Given limited information and declining production, entry is highly speculative. Consider accumulating below $4.00, closer to recent support levels, if PGM prices show sustained strength.
Exit Strategy
Take profit at $5.00+ if operational improvements are shown. Implement a stop-loss order if price breaks below $3.50 (indicating continued operational or market weakness).
Portfolio Allocation
0.5% for aggressive risk tolerance only, given high uncertainty and sector volatility.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is THAR Financially Healthy?
Valuation
P/E Ratio
655.00
Forward P/E
5.50
EV/EBITDA
655.00
Profitability
Return on Equity
-298.00%
Revenue Growth
65500.00%
EPS
$-4.11
Balance Sheet
Current Ratio
1.54
Quick Ratio
1.52
Total Debt
$655
Cash & Equivalents
$655
Cash Flow
Operating Cash Flow
$655
Free Cash Flow
$127.00M
EBITDA
$655
Other
Beta (Volatility)
-0.20
Does THAR Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Stable
Moat Sources
2 Identified
The mining industry generally has limited moats beyond resource quality and efficient operations. Commodity prices and geological factors are primary drivers, making durable moats rare.
Moat Erosion Risks
- •Declining ore grades at existing mines
- •Increasing operational costs (e.g., energy, labor)
- •New, more efficient producers entering the market
THAR Competitive Moat Analysis
Sign up to see competitive advantages
THAR Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (Limited public discussion focused on operational data)
Institutional Sentiment
Neutral (No analyst consensus or institutional ownership data available)
Insider Activity (Form 4)
No Form 4 filings or insider transactions reported in the last 90 days.
Options Flow
Normal options activity (No specific unusual activity reported in research).
Earnings Intelligence
Next Earnings
Estimated late May/early June 2026 (for Q3 FY2026 production report)
Surprise Probability
Low (Given limited data and focus on production, financial surprises are hard to predict)
Historical Earnings Pattern
No historical earnings reaction patterns available from the provided data.
Key Metrics to Watch
Competitive Position
Top Competitor
Impala Platinum (IMP) / Anglo American Platinum (AMS)
Market Share Trend
Cannot determine without market share data. Declining production metrics suggest potential pressure.
Valuation vs Peers
Cannot assess without specific valuation metrics for Tharisa plc. Generally, PGM producers trade based on commodity prices and production efficiency.
Competitive Advantages
- •Integrated PGM and chrome production (potential for cost efficiencies)
- •Established operational assets
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive THAR Stock Higher?
Near-Term (0-6 months)
- •Q3 FY2026 Production Report (Expected May/June 2026)
- •Potential stabilization or improvement in PGM commodity prices
Medium-Term (6-18 months)
- •Updates on potential expansion projects (not mentioned in current data)
- •Any indications of new resource discoveries
Long-Term (18+ months)
- •Major shifts in global PGM/chrome demand (e.g., green hydrogen, auto catalysts)
- •Consolidation within the mining sector
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for THAR?
- ✓
Consistent quarterly improvements in PGM and chrome production and grades.
- ✓
Positive commentary or guidance from management regarding future expansion or cost efficiencies.
- ✓
Strong and sustained upward trend in global PGM and chrome commodity prices.
Bull Case Analysis
See what could go right with Premium
Competing with THAR
See how THAR compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
THAR THAR | $187.4M | 1.0 | 655.0 | $655 | — | 65500.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How THAR Makes Money
Tharisa plc is a mining company primarily engaged in the extraction and production of platinum group metals (PGMs) and chrome concentrate. It operates integrated mining and processing facilities, generating revenue by selling these industrial metals to global markets. Its financial performance is heavily influenced by global demand for PGMs (used in catalytic converters, jewelry, and industrial applications) and chrome (used in stainless steel production), as well as the prevailing commodity prices for these metals.
Read Full Business Model BreakdownFAQ
What is the DVR Score for THAR (THAR)?
As of April 17, 2026, THAR has a DVR Score of 1.0 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of THAR?
THAR's market capitalization is approximately $187.4M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does THAR use?
THAR is the ticker symbol for THAR. The company trades on the NCM.
What is the risk level for THAR stock?
Our analysis rates THAR's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of THAR?
THAR currently has a price-to-earnings (P/E) ratio of 655.0. This is above the market average, suggesting the stock may be priced for high growth expectations.
Is THAR's revenue growing?
THAR has reported revenue growth of 65500.0%. The company is showing strong top-line momentum.
How often is the THAR DVR analysis updated?
Our AI-powered analysis of THAR is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 17, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for THAR (THAR) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.